Current clinical trials using ANG2 specific antibodies or an ANG1/ANG2 bispecific peptibody in combination with ICIs will also provide insight into the role of ANG2 in modulating the response to ICIs in cancer patients (Table 1). Here, ANGPT2 is linked to cancer.